Third quarter revenue grew 36% year over year, with net product sales growing 14% and total collaboration revenue growing 52%. Non-GAAP EPS rose 70%. Shares closed up 13% from the previous day's close on this news.
Eylea HD is one of the leading franchises in wet AMD and other ophthalmology markets, with Roche's Vabysmo as its main competitor.
Regeneron's pending application for US approval of Eylea HD's prefilled syringe is important for its market share.
|
Metric
|
REGN
|
RHHBY
|
NVS
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.70 | 20.45 | 16.24 |
Price/Book Value | 3.00 | 9.32 | 8.08 |
Price/Sales | 6.14 | 4.80 | 5.33 |
Price/Cash Flow | 17.77 | 15.04 | 15.65 |
|
Metric
|
REGN
|
RHHBY
|
NVS
|
|---|---|---|---|
Quick Ratio | 2.72 | 0.80 | 0.58 |
Current Ratio | 3.35 | 1.23 | 0.88 |
Interest Coverage | 106.89 | 13.49 | 8.78 |
|
Metric
|
REGN
|
RHHBY
|
NVS
|
|---|---|---|---|
Return on Assets (Normalized) | 14.40% | 15.81% | 14.70% |
Return on Equity (Normalized) | 18.83% | 48.77% | 40.76% |
Return on Invested Capital (Normalized) | 15.64% | 23.90% | 21.22% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|mWRfxK& | LOCK|Dk?%b | $135B | |||
| Moderna Inc
MRNA
| LOCK|?rBv^? | LOCK|&g | $91B | |||
| argenx SE ADR
ARGX
| LOCK|l@ZMYc! | LOCK|!cl | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|jJC@%< | LOCK|B^ | $41B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#YcYtyw | LOCK|fZwC? | $30B | |||
| Incyte Corp
INCY
| LOCK|>$npv>% | LOCK|w?^ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|Y>%!Dm | LOCK|PN | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|y!%%^TB | LOCK|Wqh<r | $21B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|MGSgszS | LOCK|&Y | $15B |
United States